APCs	antigen-presenting cells
CDK12	Cyclin-Dependent Kinase 12
CTLA-4	cytotoxic T-lymphocyte antigen-4
DCs	dendritic cells
DDR	DNA damage repair
GM-CSF	granulocyte-macrophage colony stimulating factor
dMMR	mismatch repair deficiency
HR	homologous recombination
HRD	homologous recombination deficiency
ICAM-1	intercellular adhesion molecule 1
irAEs	immune-related adverse events
LFA-3	lymphocyte function-associated antigen 3
LLO	listeriolysin O
LM	listeria monocytogenes
mCRPC	metastatic castration-resistant prostate cancer
MDSCs	myeloid-derived suppressor cells
mHSPC	metastatic hormone sensitive prostate cancer
MSI-H	high microsatellite instability
Mut/Mb	mutations/megabase
nmHSPC	non-metastatic hormone sensitive prostate cancer
ORR	overall response rate
OS	overall survival
PAP	prostatic acid phosphatase
PARPi	poly ADP ribose polymerase inhibitor
PC	prostate cancer
PD-1	programmed death receptor 1
PFS	progression-free survival
PSA	Prostate Specific Antigen
PSADT	PSA doubling time
RECIST	Response Evaluation Criteria in Solid Tumors
RP	radical prostatectomy
rPFS	progression-free survival rate
SBRT	stereotactic body radiation therapy
TILs	tumor infiltrating lymphocytes
TMB	tumor mutational burden
TRICOM	TRIad of CO-stimulatory Molecules
TRAEs	treatment-related adverse events